GE Healthcare unveils lymphoma Dx; Zimmer seals new distribution deal;

@FierceMedDev: Myriad sues Ambry over Dx gene patents. News | Follow @FierceMedDev

 @MarkHFierce: Are CT scans overused in children? A new study concludes that they are, boosting cancer risks. ICYMI yesterday | Follow @MarkHFierce

@DamianFierce: NeuroPace has hauled in another $18M to get its anti-epilepsy implant through the FDA process. Story | Follow @DamianFierce

> GE Healthcare's ($GE) Clarient has launched a diagnostic that can identify lymphoma cells with minimal tissue. News

> Zimmer ($ZMH) has signed a deal with SpineCraft to distribute that company's Apex Spine System, an FDA-cleared technology designed to correct spinal deformities. More

> The American Medical Association has assigned a unique reimbursement code for radiofrequency ablation of uterine fibroids, good news for companies like Halt Medical, which markets the Acessa system. Release

> In the face of Intuitive Surgical's ($ISRG) revenue drop and investor panic this week, other medical stocks from companies with a single product may also be at risk. Blog

> Ireland needs more skilled med tech engineers to maintain the health of its medical devices export sector, an industry CEO said recently. Story

> Chinese medical device companies should take advantage of foreign aid projects to promote their products and establish their brands around the world, government officials and industry leaders said recently. Story

Biotech News

@FierceBiotech: ChemAxon extends pharma software streak with Schrödinger deal. Article | Follow @FierceBiotech

 @JohnCFierce: When does pursuing a clinical study become unethical? Roche needs to review that question in the wake of aleglitazar fiasco. More | Follow @JohnCFierce

@RyanMFierce: Over 7 years EU & industry pumping €22.6B into R&D, €4.8B in pharma, to spur economic activity. Is it enough? Release | Follow @RyanMFierce

 @EmilyMFierce: 5 lessons from @FierceBiotech's rebooted LinkedIn group. Editor's corner | Follow @EmilyMFierce

> J&J, others back ViaCyte's stem cell therapy for diabetes in $10.6M round. Report

> 'Breakthrough' ibrutinib NDA makes rapid arrival at FDA. News

> Biotech billionaire Kirk reaches for $125M score in Intrexon IPO. Story

Pharma News

@FiercePharma: Pfizer's vaccine hope Prevenar 13 wins new EU nod in adults. Will it translate into big sales? Report | Follow @FiercePharma

 @EricPFierce: Hikma ups doxycycline capacity as it brings production back at NJ plant that got FDA warning letter. ICYMI | Follow @EricPFierce

 @CarlyHFierce: Investors unhappy with plans from Russia's Pharmstandard to spin off OTC biz. May also buy Singapore-based Bever. Yesterday's story | Follow @CarlyHFierce

> GPhA: Patent settlements saved system $25.5B. More

> Pharma, FDA still lagging in post-marketing safety research. Report

> Vivus hooks up with Menarini to hawk ED pill Spedra in $121M deal. Article

Biomarkers News

> Urine-based genetic test triumphs in trial. More

> Measuring electrical frequencies in brain could indicate Huntington's disease. Report

> U.K. Dx zeroes in on bladder cancer biomarkers in urine odor. Story

> Measuring electrical frequencies in brain could indicate Huntington's disease. Article

> Biomarker could guide decision on follow-up breast cancer treatment. News

Drug Delivery News

> Acorda grabs liquid and patch pain treatments for $8M-plus. Article

> BDSI hauls in $20M for pain film, addiction gel. More

> Oramed launches oral insulin safety trial. Report

> European injectable drug delivery market poised to soar. News

> Antibiotic-delivery strategies could cut back on side effects. Story